New targets in the treatment of anorexia nervosa

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 1, 2005, Pages 135-151

  Roerig, James L ^a,b   Mitchell, James ^a,b   Steffen, Kristine J ^b,c  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Anorexia nervosa (AN); Atypical antipsychotics; Peptides; Pharmalogical targets; Selective serotonin re uptake inhibitors (SSRIs)

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; APPETITE STIMULANT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE RECEPTOR; FLUOXETINE; HALOPERIDOL; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; NEFAZODONE; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; QUETIAPINE; RECEPTOR; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; ANOREXIA NERVOSA; BINGE EATING DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL RESEARCH; MOLECULAR INTERACTION; NEUROTRANSMISSION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PSYCHOTHERAPY; REVIEW; SATIETY; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 14744283898     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.1.135     Document Type: Review

References (198)

1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th ed). American Psychiatric Association, Washington, DC (1994):539-545.
2. AGRAS WS, BRANDT HA, BULIK CM et al.: Report of the National Institutes of Health Workshop on overcoming barriers to treatment research in anorexia nervosa. Int. J. Eat. Disord. (2004) 35:509-521.
3. HARRIS EC, BARRACLOUGH B: Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry (1997) 170 205-228.
4. HARRIS EC, BARRACLOUGH B: Excess mortality of mental disorders. Br. J. Psychiatry (1998) 173:11-53.
5. SULLIVAN PF: Mortality in anorexia nervosa. Am. J. Psychiatry (1995) 152:1073-1074.
6. BARBARICH NC, KAYE WH, JIMERSON D: Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Curr. Drug Targets CNS Neurol. Disord. (2003) 2:61-72.
7. CASPER RC: Personality features of women with good outcome from restricting anorexia nervosa. Pychosom. Med. (1990) 52 156-170.
8. SRINIVASAGAM NM, KAYE WH, PLOTNICOV KH, GREENO C, WELTZIN TE, RAO R: Persistent perfectionism, symmetry, and exactness after long-term recovery from anorexia nervosa. Am. J. Psychiatry (1995) 152 1630-1634.
9. STROBER M: Personality and symptomatological features in young, nonchronic anorexia nervosa patients. J. Pychosom. Res. (1980) 24:353-359.
10. DAVIS C, KAPTEIN S, KAPLAN A, OLMSTED M, WOODSIDE DB: Obsessionality in anorexia nervosa: the moderating influence of exercise. Psychosomatic Medicie (1998) 60:192-197.
11. HALMI KA, ECKERT E, MARCHI P, APPLE R, COHEN J: Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch. Gen. Psychiatry (1991) 48:712-719.
12. LAESSLE RG, KITTL S, FICHTER M, WITTCHEN HU, PIRKE KM: Major affective disorder in anorexia nervosa and bulimia: A descriptive diagnostic study. Br. J. Psychiatry (1987) 151:785-790.
13. TONER BB, GARFINKEL PE, GARNER DM: Affective and anxiety disorders in the long-term follow-up of anorexia nervosa. Int. J. Psychiatry Med. (1988) 18:357-360.
14. GERSHON E, SCHREIBER J, HAMOVIT J et al.: Clinical findings in patients with anorexia nervosa and affected illnesses in their relatives. Am. J. Psychiatry (1984) 149:1419-1422.
15. BRAUN DL, SUNDAY SR, HALMI KA: Psychiatric comorbidity in patients with eating disorders. Pychol. Med. (1994) 24 859-867.
16. HERZOG DB, KELLER MB, LAVORI PW, KENNY GM, SACKS NR: The prevalence of personality disorders in 210 women with eating disorders. J. Clin. Psychiatry (1992) 53:147-152.
17. IVARSSON T, RASTAM M, WENTZ E, GILLBERG I, GILLBERG C: Depressive disorders in teenage-onset anorexia nervosa: a controlled longitudinal, partly community-based study. Compr. Psychiatry (2000) 41:398-403.
18. BULIK CM, SULLIVAN PF, FEAR JL, JOYSE PR: Eating disorders and antecedent anxiety disorders: a controlled study. Acta Psychiatr. Scand. (1997) 96:101-107.
19. PLA C, TORO J: Anorexia nervosa in a Spanish adolescent sample: an 8year longitudinal study. Acta. Psychiatr. Scand. (1999) 100:441-446.
20. GODART NT, FLAMENT M, LECRUBIER Y, JEAMMET P: Anxiety disorders in anorexia nervosa and bulimia' nervosa: co-morbidity and chronology of appearance. Eur. Psychiatry (2000) 15:38-45.
21. THORNTON C, RUSSELL J: Obsessive-compulsive comorbidity in the eating disorders. Int. J. Eat. Disord. (1997) 21:83-87.
22. MACDONALD C: Treatment resistance in anorexia nervosa and the pervasiveness of ethics in clinical decision making. Can. J. Psychiatry (2002) 47:267-270.
23. TREASURE J, CAMPBELL I: The case for biology in the aetiology of anorexia nervosa. Pychol. Med. (1994) 24:3-8
24. SZABO ST, GOULD TD, MANJI HK: Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders. In: Textbook of Pychopharmacology (3rd Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc, Washington, DC (2004):3-52.
25. BLUNDELL JE: Serotonin and appetite. Neuropharmacology (1984) 23:1537-1551.
26. LEIBOWITZ SF, SHOR-POSNER G: Brain serotonin and eating behavior. Appetite. (1986) 7(Suppl.):1-14.
27. BREWERTON T. Toward a unified theory of serotonin dysregulation in eating and related disorders. Pychoneuroendocrinology (1995) 20:561-590.
28. KAYE WH, EBERT MH, RALEIGH M, LAKE R: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch. Gen. Psychiatry (1984) 41:350-355.
29. KAYE WH, GWIRTSMAN HE, GEORGE DT, JIMERSON DC, EBERT MH: CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol. Psychiatry. (1988) 23:102-105.
30. HADIGAN CM, WALSH BT, BUTTINGER C, HOLLANDER E: Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa. Biol. Psychiatry (1995) 37:504-511.
31. FRANK GK, KAYE WH, MELTZER CC et al.: Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol. Psychiatry. (2002) 52:896-906.
32. KAYE WH, GWIRTSMAN HE, GEORGE DT, EBERT MH: Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch. Gen. Psychiatry (1991) 48:556-62.
33. FRANK GK, KAYE WH, WELTZIN TE et al.: Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int. J. Eat. Disord. (2001) 30:57-68.
34. KAYE WH, BARBARICH NC, PUTNAM K et al.: Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. Int. J. Eat. Disord. (2003) 33:257-267.
35. SZABO ST, BLIER P: Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA (A) receptors: a microiontophoretic study in the rat locus ceruleus. Synapse (2001) 42:203-212.
36. FERGUSON CP, LA VIA MC, CROSSAN PJ, KAYE WH: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int. J. Eat. Disord. (1999) 25:11-17.
37. ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548-551.
38. BARBARICH NC, MCCONAHA CW, HALMI KA et al.: Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. J. Eat. Disord. (2004) 35 10-15.
39. ANDERSON IM, PARRY-BILLINGS M, NEWSHOLME EA, FAIRBURN CG, COWEN PJ: Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychol. Med. (1990) 20:785-791
40. FAVARO A, CAREGARO L, BURLINA AB, SANTONASTASO P: Tryptophan levels, excessive exercise, and nutritional status in anorexia nervosa. Psychosom. Med. (2000) 62:535-538.
41. KAYE WH, FRANK GK, MCCONAHA C: Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology (1999) 21:503-506.
42. WATANABE T, TAGUCHI Y, MAEYAMA K: Enzymes involved in histamine metabolism. In: Histaminergic Neurons: Morphology and Function. Watanabe T, Wada H (Eds), CRC Press, Boca Raton (1991):11-34.
43. RICHELSON E: Histamine receptors in the central nervous system. In: The Histamine Receptor. Schwartz J, Haas HL (Eds), Wiley-Liss, Inc, New York (1992):271-295.
44. GLAESER BS, MAHER TJ, WURTMAN RJ: Changes in brain levels of acidic, basic, and neutral amino acids after consumption of single meals containing various proportions of protein. J. Neurochem. (1983) 41:1016-1021.
45. SCHWARTZ JC, LAMPART C, ROSE C: Histamine formation in rat brain in vivo: effects of histidine loads. J. Neurochem. (1972) 19:801-810.
46. ITOWI N, NAGAI K, NAKAGAWA H, WATANABE T, WADA H: Changes in the feeding behavior of rats elicited by histamine infusion. Physiol. Behav. (1988) 44:221-226.
47. SHEINER JB, MORRIS P, ANDERSON GH: Food intake suppression by histidine. Pharmacol. Biochem. Behav. (1985) 23:721-726.
48. FUKAGAWA K, SAKATA T, SHIRAISHI T et al.: Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. J. Am. Physiol. Soc. (1989) 89:R605-R611.
49. 3 Receptors. Eur. J. Pharmacol. (1990) 184:135-142.
50. MERCER LP, SAXON KELLY D, HUMPHRIES LL, DUNN JD: Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J. Nutr. (1994) 124:1029-1036.
51. MERCER LP, DODDS SJ, SCHWEISTHAL MR, DUNN JD: Brain histidine and food intake in rats fed diets deficient in single amino acids. J. Nutr. (1989) 11:66-74.
52. PAO SK, DICKERSON JW. Effect of a low protein diet and isoenergetic amounts of a high protein diet in the weanling rat on the free amino acids of the brain. Nutr. Metabol. (1975) 18 204-216.
53. LUNN PG, AUSTIN S: Differences in nitrogen metabolism between protein-deficient and energy deficient rats with similarly restricted growth rates. Ann. Nutr. Metab. (1983) 27:242-251.
54. MERCER LP, KELLEY DS, HAQ A, HUMPHRIES LL: Dietary induced anorexia: a review of involvement of the histaminergic system. J. Am. Coll. Nutr. (1996) 15:23-230.
55. TAYLOR DM, McASKILL R: Atypical antipsychotics and weight gain: a systematic review. Acta Pychiatrica Scandinavica (2000). 101:416-432.
56. MCINTYRE RS, MANCINI DA, BASILE VS: Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiat. (2001) 62 Suppl. 23):23-29.
57. WETTERLING T: Body weight gain with atypical antipsychotics: A comparative review. Drug Saf. (2001) 24:59-73.
58. WEINSIER RL, HUNTER GR, HEINI AF, GORAN MI, SELL SM: The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am. J. Med. (1998) 105:145-150.
59. BAPTISTA T, LACRUZ A, ANGELES F et al.: Endocrine and metabolic profile in the obesity associated to typical antipsychotic drug-administration. Pharmacopsychiatry (2001) 34:223-231.
60. MCINTYRE RS, MANCINI DA, BASILE VS: Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiat. (2001) 62 Suppl. 23):23-29.
61. KROEZE WK, HUFEISEN SJ, POPADAK BA et al.: H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28 519-526.
62. MULLER DJ, MUGLIA P, FORTUNE T, KENNEDY JL: Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol. Res. (2004) 49 309-329.
63. POWERS PS, BANNON Y, EUBANKS R. Anorexia nervosa and atypical antipsychotics: effect on weight and psychopathology. Eating Disorders Research Society annual meeting Ravello Italy (2003):65.
64. VANDEREYCKEN W, PIERLOOT R: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. (1982) 66(6):445-450.
65. VANDEREYCKEN W: Neuroleptics in the short-term treatment of anotexia nervosa: a double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry (1984) 144:288-292.
66. DALLY P, SARGANT W: A new treatment of anorexia nervosa. Br. Med. J. (1960) 1:1770-1773.
67. GARDOS G, COLE JO: Overview: public health issues in tardive dyskinesia. Am. J. Psychiatry (1980) 137:776-781.
68. DULCAN MK, BREGMAN J, WELLER EB, WELLER R: Treatment of childhood and adolescent disorders. In: Essentials of Clinical Pychopharmacology. Schatzberg AF, Nemeroff CB, American Psychiatric Publishing, Inc. Washington DC (2001):459-517.
69. CONDON JT: Long-term neuroleptic therapy and chronic anorexia nervosa complicated by tardive dyskinesia. A case report. Acta Psychiatr. Scand. (1986) 73:203-206.
70. WEIZMAN A, TYANO S, WIJSENBEEK H, BEN DAVID M: Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychother. Psychosom. (1985) 43:136-140.
71. MARDER SR, WIRSHING DA: Clozapine. In: Textbook of Pychopharmacology (3rd Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington DC (2004):443-456.
72. KAPUR S, SRIDHAR N, REMINGTON G: The newer antipsychotics: underlying mechanisms and the new clinical realities. Curr. Opin. Psychiatry (2004) 17:115-122.
73. HARVEY PD, KEEFE RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry (2001) 158:176-184.
74. MELTZER HY, MCGURK SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. (1999) 25:233-255.
75. MELTZER HY, SUMIYOSHI T: Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry (2003) 53 265-270.
76. GREEN MF, MARDER SR, GLYNN SM et al.: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological Psychiatry (2002) 51:972-978.
77. CARPENTER WT, GOLD JM: Another view of therapy for cognition in schizophrenia. Biological Psychiatry (2002) 51:969-971.
78. BILDER RM, GOLDMAN RS, VOLAVKA J et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Pyschiatry (2002) 159:1018-1028.
79. KEEFE RS, SEIDMAN LJ, CHRISTENSEN BK et al.: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Pyschiatry (2004) 161:985-995.
80. HALMI KA, ECKERT E, FALK JR: Cyproheptadine for anorexia nervosa. Lancet (1982) 1:1357-1358.
81. MASAN PS: Atypical antipsychotics in the treatment of affective symptoms: a review. Ann. Clin. Psychiatry (2004) 16 3-13.
82. GOLDEN RN, DAWKINS K, NICHOLS L: Trazodone and nefazodone. In: Textbook of Psychopharmacology (3rd Edn). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington, DC (2004):315-326.
83. CASSANO GB, MINIATI M, PINI S et al.: Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int. J. Eat. Disord. (2003) 33:172-177.
84. NINAN PT, MUNTASSER S: Buspirone and gepirone. In: Textbook of Psychopharmacology (3rd Edn). Schatzberg AF, Nemeroff CB. (Ed.), American Psychiatric Publishing, Inc. Washington, DC (2004):391-404.
85. KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind, placebo-controlled, administration of fluoxetine in restricting- and purging-type anorexia nervosa. Biol. Psychiatry (2001) 49 644-652.
86. ROSENBAUM JF, TOLLEFSON GD: Fluoxetine. In: Textbook of Psychopharmacology (3rd Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington, DC (2004):231-146.
87. FLORES BH, SCHATZBERG AF: Mirtazapine. In: Textbook of Psychopharmacology (3rd Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC (2004):341-348.
88. SCHULE C, BAGHAI T, ZWANZGER P et al.: Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (2003) 166:271-275.
89. MORLEY JE, BLUNDELL JE: The neurobiological basis of eating disorders: some formulations. Biol Psychiatry (1988) 23 53-78.
90. SCHWARTZ MW, WOODS SC, PORTE D JR, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404 661-671.
91. JIMERSON DC, WOLFE BE, NAAB S: In: Anorexia nervosa and bulimia nervosa. Coffee CE, Brumback RA (Eds), American Psychiatric Press Inc., Washington DC (1998):563-578
92. STOVING RK, HANGAARD J, HANSEN-NORD M, HAGEN C: A review of endocrine changes in anorexia nervosa. J. Psychiatr. Res. (1999) 33:139-152.
93. VALE W, SPIESS J, RIVIER C, RIVIER J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 213 1394-1397.
94. GOLD PW, GWIRTSMAN H, AVGERINOS PC et al.: Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N. Engl. J. Med. (1986) 314:1335-1342.
95. KAYE WH, GWIRTSMAN HE, GEORGE DT et al.: Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J. Clin. Endocrinol. Metab. (1987) 64:203-208.
96. LICINIO J, WONG ML, GOLD PW: The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Res. (1996) 62:75-83.
97. WALSH BT, ROOSE SP, KATZ JL et al.: Hypothalamic-pituitary-adrenal-cortical activity in anorexia nervosa and bulimia. Psychoneuroendocrinology (1987) 12:131-140.
98. GLOWA JR, GOLD PW: Corticotropin releasing hormone produces profound anorexigenic effects in the rhesus monkey. Neuropeptides (1991) 18:55-61.
99. RIVIER C, VALE W: Corticotropin-releasing factor (CRF) acts centrally to inhibit growth-hormone secretion in the rat. Endocrinology (1984) 114:2409-2411.
100. SIRINATHSINGHJI DJ: Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat. Brain Res. (1982) 407:185-190.
101. SUTTON RE, KOOB GF, LeMOAL M, RIVIER J, VALE W: Corticotropin releasing factor produces behavioral activation in rats. Nature (1982) 297:331-333.
102. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. (2000) 34:171-181.
103. PLOTSKY PM: Pathways to the secretion of adrenocorticotropin: a view from the portal. J. Neuroendocrinol. (1991) 3:1-9.
104. HOLSBOER F: Neuroendocrinology of mood disorders. In: Psychopharmacology: the fourth generation of progress. Bloom FE, Kupfer DJ (Eds), Raven Press, New York (1995):957-969.
105. OWENS MJ, NEMEROFF CB: Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. (1991) 43 425-473.
106. HOLSBOER F, SPENGLER D, HEUSER I: The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog. Brain Res. (1992) 93:385-417.
107. MORLEY JE, LEVINE AS, GOSNELL BA, MITCHELL JE, KRAHN DD, NIZIELSKI SE: Peptides and feeding. Peptides (1985) 6(Suppl. 2):181-192.
108. BREWERTON TD, LYDIARD RB, LARAIA MT, SHOOK JE, BALLENGER JC: CSF beta-endorphin and dynorphin in bulimia nervosa. Am. J. Psychiatry (1992) 149:1086-1090.
109. KAYE WH, BERRETTINI WH, GWIRTSMAN HE et al.: Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including beta-endorphin) in anorexia nervosa. Life Sci. (1987) 41:2147-2155.
110. LESEM MD, BERRETTINI WH, KAYE WH, JIMERSON DC: Measurement of CSF dynorphin A 1-8 immunoreactivity in anorexia nervosa and normal-weight bulimia. Biol. Psychiatry (1991) 29:244-252.
111. BRAMBILLA F, BRUNETTA M, PEIRONE A et al.: T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. anorexia nervosa. Psychiatry Res. (1995) 59:43-50.
112. KALRA SP, DUBE MG, FOURNIER A, KALRA PS: Structure-function analysis of stimulation of food intake by neuropeptide Y: effects of receptor agonists. Physiol. Behav. (1991) 50:5-9.
113. KAYE WH, BERRETTINI W, GWIRTSMAN H, GEORGE DT: Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch. Gen. Psychiatry (1990) 47 548-556.
114. BARANOWSKA B, WOLINSKA-WITORT E, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, CHMIELOWSKA M: Plasma leptin, neuropeptide Y (NPY) and galanin concentrations in bulimia nervosa and in anorexia nervosa. Neuroendocrinol. Lett. (2001) 22:356-358.
115. KORNER J, LEIBEL RL: To eat or not to eat - how the gut talks to the brain. N. Engl. J. Med. (2003) 349:926-928.
116. NEARY NM, SMALL C J, BLOOM S R: Gut and mind. Gut (2003) 52:918-921.
117. MONTELEONE P, LONGOBARDI N, FUSCHINO A, FABRAZZO M, MAJ M: Peripheral ghrelin and PYY responses to food intake and short term fasting implications for eating behavior and gastrointestinal physiology in Bulimia nervosa. Eating Disorders Research Society annual meeting Ravello Italy (2003):40.
118. 3-36 physiologically inhibits food intake. Nature (2002) 418:650-654.
119. 3-36. N. Engl. J. Med. (2003) 349:941-948.
120. HORVATH TL, DIANO S, SOTONYI P, HEIMAN M, TSCHO MP: Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 142:4163-4169.
121. WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86:5992-5995.
122. OTTO B, CUNTZ U, FRUEHAUF E et al.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. (2001) 145:669-673.
123. CUMMINGS DE, SHANNON MH: Roles for ghrelin in the regulation of appetite and body weight. Arch Surg. (2003) 138:389-396.
124. KEIRE DA, MANNON P, KOBAYASHI M, WALSH JH, SOLOMON TE, REEVE JR: Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am. J. Physiol. Gastrointest Liver Physiol. (2000) 279:G126-G131.
125. BROBERGER C, LANDRY M, WONG H, WALSH JN, HOKFELT T: Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology (1997) 66 393-408.
126. GIBBS J, YOUNG RC, SMITH GP: Cholecystokinin decreases food intake in rats. J. Comp. Physiol. Psychol. (1973) 84:488-495.
127. LIDDLE RA, GERTZ BJ, KANAYAMA S et al.: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J. Clin. Invest. (1989) 84:1220-1225.
128. LIDDLE RA, MORITA ET, CONRAD CK, WILLIAMS JA: Regulation of gastric emptying in humans by cholecystokinin. J. Clin. Invest. (1986) 77:992-996.
129. TAMAI H, TAKEMURA J, KOBAYASHI N, MATSUBAYASHI S, MATSUKURA S, NAKAGAWA T: Changes in plasma cholecystokinin concentrations after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism (1993) 42:581-584.
130. HARTY RF, PEARSON PH, SOLOMON TE, MCGUIGAN JE: Cholecystokinin, vasoactive intestinal peptide and peptide histidine methionine responses to feeding in anorexia nervosa. Regul. Pept. (1991) 36:141-150.
131. BARANOWSKA B, RADZIKOWSKA M, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, BOROWIEC M: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes. Metab. (2000) 2 99-103.
132. PIRKE KM, KELLNER MB, FRIESS E, KRIEG JC, FICHTER MM: Satiety and cholecystokinin. Int. J. Eat. Disord. (1994) 15:63-69.
133. GIBBS J, SMITH GP: Satiety: the roles of peptides from the stomach and the intestine. Fed Proc. (1986) 45:1391-1395.
134. GUTZWILLER JP, DREWE J, HILDEBRAND P, ROSSI L, LAUPER JZ, BEGLINGER C: Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology (1994) 106:1168-1173.
135. LIDDLE RA, GERTZ BJ, KANAYAMA S et al.: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J. Clin. Invest. (1989) 84:1220-1225.
136. KISSILEFF HR, VAN ITALLIE TB: Physiology of the control of food intake. Ann. Rev. Nutr. (1982) 2:371-418.
137. PEIKIN SR: Role of cholecystokinin in the control of food intake. Gastroenterol. Clin. North Am. (1989) 18:757-775.
138. LIDDLE RA, GOLDFINE ID, ROSEN MS, TAPLITZ RA, WILLIAMS JA: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. (1985) 75:1144-1152.
139. LIDDLE RA, GOLDFINE ID, WILLIAMS JA: Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology (1984) 87:542-549.
140. MORAN TH, AMEGLIO PJ, PEYTON HJ, SCHWARTZ GJ, MCHUGH PR: Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am. J. Physiol. (1993) 265(3 Pt 2):R620-R624.
141. MORAN TH, AMEGLIO PJ, SCHWARTZ GJ, MCHUGH PR: Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am. J. Physiol. (1992) 262(1 Pt 2):R46-R50.
142. BEGLINGER C, DEGEN L, MATZINGER D, D'AMATO M, DREWE J: Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. J. Physiol. Regul Integr Comp Physiol. (2001) 280:R1149-R1154.
143. LIEVERSE RJ, MASCLEE AA, JANSEN JB, ROVATI LC, LAMERS CB: Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Biol. Psychiatry (1995) 37:331-335.
144. ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425-432.
145. PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269:540-543.
146. HALAAS JL, GAJIWALA KS, MAFFEI M et al.: Weight reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269:543-546.
147. CAMPFIELD LA, SMITH FJ, GUISEZ Y, DEVOS R, BURN P: Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (1995) 269 546-549.
148. MONTAGUE CT, FAROOQI IS, WHITEHEAD JP et al.: Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature (1997) 387:903-908.
149. CONSIDINE RV, CONSIDINE EL, WILLIAMS CJ, HYDE TM, CARO JF: The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes (1996) 45:992-994.
150. SCHWARTZ MW, PESKIND E, RASKIND M, BOYKO EJ, PORTE D J: Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. (1996) 2:589-593.
151. CONSIDINE RV, SINHA MK, HEIMAN ML et al.: Serum immunoreactive-leptin concentrations in normal weight and obese humans. N. Engl. J. Med. (1996) 334:292-295.
152. ECKERT ED, POMEROY C, RAYMOND N, KOHLER PF, THURAS P, BOWERS CY: Leptin in anorexia nervosa. J. Clin. Endocrinol. Metab. (1998) 83:791-795.
153. MANTZOROS C, FLIER JS, LESEM MD, BREWERTON TD, JIMERSON DC: Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. J. Clin. Endocrinol. Metab. (1997) 82:1845-1851.
154. EXNER C, HEBEBRAND J, REMSCHMIDT H, WEWETZER C, ZIEGLER A, HERPERTZ S: Leptin suppresses semi-starvation-induced hyperactivity in rats: implications for anorexia nervosa. Mol. Psychiatry (2000) 5:476-481.
155. HOLTKAMP K, HERPERTZ-DAHLMANN B, MIKA C, HEER M, HEUSSEN N, FICHT HERPERTZ S: Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. (2003) 88:5169-5174.
156. MONTELEONE P, LONGOBARDI N, FUSCHINO A, FABRAZZO M, MAJ M: Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J. Clin. Psychopharmacol. (2002) 22:424-426.
157. FREDERICH R, HU S, RAYMOND N, POMEROY C: Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretation. J. Lab. Clin. Med. (2002) 139:72-79.
158. JIMERSON DC: Leptin and the neurobiology of eating disorders. J. Lab. Clin. Med. (2002) 139:70-71.
159. HOLTKAMP K, HEBEBRAND J, MIKA C, HEER M, HEUSSEN N, HERPERTZ-DAHLMANN B: High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa. Pychoneuroendocrinology (2004) 29:791-797.
160. GENDALL KA, KAYE WH, ALTEMUS M, MCCONARA CW, LA VIA MC: Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biol. Psychiatry (1999) 46:292-299.
161. YANG YK, HARMON CM: Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes. Rev. (2003) 4:239-48.
162. ADAN R, HILLEBRAND J, RUKE C et al.: Melanocortin system and eating disorders. Ann. NY Acad. Sci. (2003) 994 267-274.
163. ARGYROPOULOS G, RANKINEN T, NEUFELD DR et al.: A polymorphism in the human agouti-related protein is associated with late-onset obesity. J Clin. Endocrinol. Metab. (2002) 87 4198-4202.
164. FAN W, BOSTON BA, KESTERSON RA, HRUBY VJ, CONE RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165-168.
165. KALRA SP, HORVATH TL: Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Ann. NY Acad. Sci. (1998) 863:236-240.
166. CRAWELY JN: The role of galanin in feeding behavior. Neuropeptides (1999) 35:369-375.
167. LEIBOWITZ SF: Brain peptides and obesity: pharmacologic treatment. Obes. Res. (1995) 3(Suppl. 4):573S-589S.
168. FRANK GK, KAYE WH, SAHU A, FERNSTROM J, MCCONAHA C: Could reduced cerebrospinal fluid (CSF) galanin contribute to restricted eating in anorexia nervosa? Neuropsychopharmacology (2001) 24 706-709.
169. BERRETTINI W, KAYE W, SUNDERLAND T et al.: Galanin immunoreactiviry in human CSF: studies in eating disorders and Alzheimer's disease. Neuropsychobiology (1988) 19:64-68.
170. INVITTI C, BRUNANI A, PASQUALINOTTO, L et al.: Plasma galanin concentrations in obese, normal weight and anorectic women. Int. J. Obes. Relat. Metab. Disord. (1995) 19:347-349.
171. BARANOWKA B, WOLINSKA-WITORT E, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, CHMIELOWKSA M: Plasma leptin, neuropeptide Y (NPY), and galanin concentrations in bulimia nervosa and anorexia nervosa. Neuroendocrinology Letters (2001) 22:356-358.
172. BARANOWSKA B, RADZIKOWSKA M, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, BOROWIEC M: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Obesity Metab. (2000) 2:99-103.
173. BARANOWKSA B, WASILEWSKA-DZIUBINSKA E, RADZIKOWSKA M, PLONOWSKI A, ROGUSKI K: Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa. Metabolism (1997) 46:1384-1389.
174. DE MARINIS L, MANCINI A, VALLE D et al.: Effects of galanin on growth hormona and prolactin secretion in anorexia nervosa. Metabolism (2000) 49:155-159.
175. ERSPAMER V, ERPAMER GF, INSELVINI M: Some pharmacological actions of alytesin and bombesin. J. Pharm. Pharmacol. (1970) 22 875-876.
176. ANASTASI A, ERSPAMER V, BUCCI M: Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alyres. Experientia (1971) 27 166-167.
177. MCDONALD TJ, JORNVALL H, NILSSON G et al.: Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem. Biophys. Res. Commun. (1979) 90 227-33.
178. MINAMINO N, KANGAWA K, MATUSO H: Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun. (1983) 114:541-548.
179. MINAMINO N, KANGAWA K, MATSUO H: Neuromedin B and neuromedin Ca. Two mammalian bombesin-like peptides identified in porcine spinal cord and brain. Ann. NY Acad. Sci. (1988) 547:373-390.
180. GIBBS J, FASUER DJ, ROWE EA, ROLLS BJ, ROLLS ET, MADDISON SP: Bombesin suppresses feeding in rats. Nature. (1979) 282 208-10.
181. FATHI Z, BENYA RV, SHAPIRA H, JENSEN RT, BATTEY JF: The fifth transmembrane segment of the neuromedin B receptor is critical for high affinity neuromedin B binding. J. Biol. Chem. (1993) 268 14622-14626.
182. YAMADA K, WADA E, SANTO-YAMADA Y, WADA K: Bombesin and its family of peptides: prospects for the treatment of obesity. Eur. J. Pharmacol. (2002) 440:281-90
183. MERALI Z, MCINTOSH J, ANISMAN H: Role of bombesin related peptides in the control of food intake. Neuropeptides (1999) 33 376-386.
184. MITCHELL JE, GOSNELL BA, ROERIG JL et al.: Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obes. Res. (2003) 11:599-602.
185. FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and autistic disorder in an adolescent girl. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:937-940.
186. HANSEN L: Olanzapine in the treatment of anorexia nervosa. Br. J. Psychiatry (1999) 175:592.
187. JENSEN VS, MEJLHEDE A: Anorexia nervosa: treatment with olanzapine. Br. J. Psychiatry (2000) 177:187.
188. LA VIA MC, GRAY L, KAYE WH: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord. (2000) 27 363-366.
189. NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child. Adolesc. Psychiatry (2000) 39:941-942.
190. GASKILL JA, TREAT TA, MCCABE EB, MARCUS MD: Does olanzapine
191. MEHLER C, WEWETZER C, SCHULZE U, WARNKE A, THEISEN F, DITTMANN RW: Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur. Child. Asolesc. Psychiatry (2001) 10:151-157.
192. RUGGIERO GM, LAINI V, MAURI MC: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog. Neuropsychopharmacol. Biol. Psychiat. (2001) 25:1049-1059.
193. CARVER AE, MILLER S, HAGMAN J, SIGEL E: The use of risperidone for the treatment of anorexia nervosa. Academy of Eating Disorders Annual Meeting, Boston, USA, April (2002).
194. POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32:146-154.
195. BOACHIE A, GOLDFIELD GS, SPETTIQUE W: Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int. J. Eat. Disord. (2003) 33(1):98-103.
196. BOSANAC P, BURROWS G, NORMAN T. Olanzapine in anorexia nervosa. Aust. NZ J. Psychiatry (2003) 37:494.
197. ERCAN ES, COPKUNOL H, CYKOETHLU S, VARAN A: Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum. Pychopharmacol. (2003) 18:401-403.
198. MALINA A, GASKILL J, MCCONAHA C et al.: Olanzapine treatment of anorexia nervosa: a retrospective study. Int. J. Eat. Disord. (2003) 33:234-237.